Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-04-05
2011-04-05
Goldberg, Jeanine A (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C435S091200, C536S023100, C536S024300
Reexamination Certificate
active
07919251
ABSTRACT:
The present invention provides methods for predicting tolerance associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. In particular, the present invention provides methods for predicting a patient's risk of an adverse drug reaction (or tolerance) to a 6-mercaptopurine drug by genotyping a patient at a polymorphic site in at least one gene selected from the group consisting of a xanthine dehydrogenase (XDH) gene, molybdenum cofactor sulfurase (MOCOS) gene, and aldehyde oxidase (AOX) gene. The present invention further provides methods for optimizing therapeutic efficacy in a patient receiving a 6-mercaptopurine drug by determining whether the patient should be given an alternative drug based on the presence or absence of a polymorphism in at least one of the XDH, MOCOS, and AOX genes.
REFERENCES:
patent: 5691343 (1997-11-01), Sandborn
patent: 6987097 (2006-01-01), Seidman et al.
patent: 2005/0202483 (2005-09-01), Sanderson et al.
patent: 2005/0227917 (2005-10-01), Williams et al.
patent: 2007/0031846 (2007-02-01), Cargill et al.
patent: WO 2005/078125 (2005-08-01), None
patent: WO 2007/073478 (2007-06-01), None
Smith et al. Aliment Pharmacol Ther, vol. 30, pp. 375-384, 2009.
Rashidi et al, Drug Metabolism and Pharmacokinetics, vol. 22, No. 4, pp. 299-306, Aug. 2007.
Genbank dbSNP rs5575465, Sep. 18, 2007.
Dubinsky, et al.; 6-MP Metabolite Profiles Provide a Biochemical Explanation for 6-MP Resistance in Patients with Inflammatory Bowel Disease; Gastroenterology 2002:122:904-915.
Lennard, et al.; Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism; Clin Pharmacol Ther; Aug. 1989; 46:149-54.
Mardini, et al.; Utility of Measuring 6-Methylmercaptopurine and 6-Thioguanine Nucleotide Levels in Managing Inflammatory Bowel Disease Patients Treated with 6-Mercaptopurine in a Clinical Practice Setting; J Clin Gastroenterol 2003: 36(5):390-395.
Papadakis; Optimizing the Therapeutic Potential of Azathioprine/6-Mercaptopurine in the Treatment of Inflammatory Bowel Disease; J Clin Gastroenterol 2003:36(5):379-385.
Present, et al.; 6-Mercaptopurine in the Management of Inflammatory Bowel Disease: Short and Long-Term Toxicity; Annals of Internal Medicine 1989: 111:641-649.
Valik et al.; Hereditary Disorders Of Purine and Pyrimidine Metabolism: Identification Of Their Biochemical Phenotypes In the Clinical Laboratory; Mayo Clin Proc; Aug. 1997, 72:719-725.
Hawwa et al. “Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine,” British Journal of Clinical Pharmacology, vol. 66, No. 4, pp. 517-528, 2008.
Katsanos et al. “Analysis of genetic variants in non-TPMT genes to explain bone marrow toxicity during azathioprine therapy in inflammatory bowel disease,” XP002516154, Digestive Disease Week Meeting/109thAnnual Meeting of the American-Gastroenterological-Association, 2008, vol. 134, No. 4, Suppl. 1, Database accession No. PREV200800414803, Database BIOSIS [Online] Biosciences Information Service [Abstract].
Katsanos et al. “Azathioprine/6-mercaptopurine toxicity: The role of the TPMT gene,” Annals of Gastroenterology, 2007, vol. 20, No. 4, pp. 251-264.
Rashidi et al. “In Vitro Study of 6-mercaptopurine Oxidation Catalysed by Aldehyde Oxidase and Xathine Oxidase,” Drug Metab. Pharmacokinet. 2007, vol. 22, No. 4, pp. 299-306.
Smith et al. “Common polymorphism in the aldehyd oxidase gene is a marker of non-response to azathioprine therapy in inflammatory bowel disease,” XP002516153, Annual General Meeting of the British-Society-of-Gastroenterology, 2008, vol. 57, Suppl. 1. p. A36, Database Accession No. PREV200800333950, Database BIOSIS [Online] Biosciences Information Service [Abstract].
Smith et al. “Seeking pharmacogenetic loci which explain non-thiopurine methyltransferase related side effects in patients taking azathioprine for inflammatory bowel disease,” XP002516152, Annual General Meeting of the British-Scoiety-of-Gastroenerology, 2008, vol. 57, Suppl. 1, p. A148, Database Accession No. PREV200800334244, Database BIOSIS [Online] Biosciences Information Service [Abstract].
Marinaki Anthony M.
Sanderson Jeremy D.
Smith Melissa A.
Goldberg Jeanine A
Guy's and St. Thomas' NHS Foundation Trust
Kilpatrick Townsend & Stockton LLP
LandOfFree
Non-thiopurine methyltransferase related effects in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-thiopurine methyltransferase related effects in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-thiopurine methyltransferase related effects in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2710497